ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 35 filers reported holding ASCENDIS PHARMA A/S in Q2 2017. The put-call ratio across all filers is - and the average weighting 1.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,880,854 | -7.1% | 57,786 | +3.0% | 0.00% | 0.0% |
| Q1 2024 | $8,480,939 | +22.2% | 56,102 | +1.8% | 0.00% | 0.0% |
| Q4 2023 | $6,938,585 | +35.8% | 55,090 | +1.0% | 0.00% | 0.0% |
| Q3 2023 | $5,108,530 | +6.9% | 54,555 | +1.8% | 0.00% | 0.0% |
| Q2 2023 | $4,780,676 | -13.8% | 53,565 | +3.5% | 0.00% | 0.0% |
| Q1 2023 | $5,546,812 | +88620.6% | 51,733 | +1.1% | 0.00% | 0.0% |
| Q4 2022 | $6,252 | -99.9% | 51,192 | +0.0% | 0.00% | 0.0% |
| Q3 2022 | $5,285,000 | +14.4% | 51,186 | +3.0% | 0.00% | 0.0% |
| Q2 2022 | $4,619,000 | -17.7% | 49,696 | +3.9% | 0.00% | 0.0% |
| Q1 2022 | $5,615,000 | -10.9% | 47,850 | +2.1% | 0.00% | 0.0% |
| Q4 2021 | $6,305,000 | -11.7% | 46,873 | +4.6% | 0.00% | 0.0% |
| Q3 2021 | $7,140,000 | +22.6% | 44,796 | +1.2% | 0.00% | 0.0% |
| Q2 2021 | $5,824,000 | +4.0% | 44,277 | +1.9% | 0.00% | 0.0% |
| Q1 2021 | $5,601,000 | -21.6% | 43,463 | +1.4% | 0.00% | 0.0% |
| Q4 2020 | $7,148,000 | +18.2% | 42,864 | +9.4% | 0.00% | 0.0% |
| Q3 2020 | $6,048,000 | +6.9% | 39,196 | +2.4% | 0.00% | 0.0% |
| Q2 2020 | $5,660,000 | +34.3% | 38,273 | +2.2% | 0.00% | 0.0% |
| Q1 2020 | $4,215,000 | -53.6% | 37,432 | -42.7% | 0.00% | 0.0% |
| Q4 2019 | $9,082,000 | +190.1% | 65,294 | +100.8% | 0.00% | 0.0% |
| Q3 2019 | $3,131,000 | -16.8% | 32,515 | -0.5% | 0.00% | 0.0% |
| Q2 2019 | $3,764,000 | +2.9% | 32,691 | +5.2% | 0.00% | 0.0% |
| Q1 2019 | $3,657,000 | -5.1% | 31,073 | -49.5% | 0.00% | 0.0% |
| Q4 2018 | $3,852,000 | +99.3% | 61,486 | +125.4% | 0.00% | 0.0% |
| Q3 2018 | $1,933,000 | +7.5% | 27,284 | +0.9% | 0.00% | 0.0% |
| Q2 2018 | $1,798,000 | +32.4% | 27,042 | +30.2% | 0.00% | – |
| Q1 2018 | $1,358,000 | +66.4% | 20,775 | +1.9% | 0.00% | – |
| Q4 2017 | $816,000 | +12.9% | 20,390 | +2.1% | 0.00% | – |
| Q3 2017 | $723,000 | +32.4% | 19,972 | +1.5% | 0.00% | – |
| Q2 2017 | $546,000 | +31.9% | 19,686 | +32.9% | 0.00% | – |
| Q1 2017 | $414,000 | – | 14,817 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |